Skip to main content

Pfizer Expands License to Entelos Software


Entelos said this week that Pfizer has taken a non-exclusive perpetual license to its Metabolism Physiolab platform.

Under the terms of the license, which expands on a previous agreement between the firms, Pfizer will have access to both Entelos’ PhysioLab Modeler software and its PhysioLab Simulation Server to study the biological mechanisms underlying disease.

Further details about the terms of the license were not disclosed.

The two companies announced a research partnership based on the Entelos Cardiovascular PhysioLab platform in 2007 following an earlier announcement that a subsidiary of Pfizer based in Ireland had agreed to purchase more than 2.5 million Entelos shares worth $1.5 million (BioInform 11/16/2007).

At the time of the original announcement, Entelos disclosed that the research would be focused on identifying biomarkers and interpreting clinical study data.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.